PCA3 Test May Help Distinguish Aggressive Prostate Cancer
The PCA3 Test May Help Distinguish Between Benign and Aggressive
The answer may well be given by the PCA3 (Prostate Cancer Gene 3) test, a breakthrough in the diagnosis of prostate cancer. The genetic test was developed in the laboratory of the Radboud University in Nijmegen (NL) by a team headed by Professor Jack Schalken.
PCA3 is a new tool available in a simple urine test to help make better biopsy decisions - in combination with Prostate Specific Antigen (PSA) - in the diagnosis of prostate cancer. It is available as the PROGENSA(TM) PCA3 assay in Europeand is the first gene-based diagnostic test in this field. It is an efficient tool to help decide if prostate biopsy is really needed to diagnose prostate cancer in men suspected of having the condition. PCA3 is, unlike PSA, prostate cancer specific. This means that the gene is only produced by prostate cancer cells and is not affected by prostate size. It discriminates better than PSA between prostate cancer and benign/non-cancerous prostate diseases such as benign prostatic hyperplasia (BPH, i.e. prostate enlargement) or prostatitis (infection of the prostate). Therefore, PCA3 gives very useful information in deciding if a biopsy is really needed.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.